Your session is about to expire
← Back to Search
Ticagrelor for Heart Attacks and Stable Angina
Study Summary
This trial finds that ticagrelor is associated with less cardiovascular events and all-cause mortality than clopidogrel in patients with acute coronary syndromes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function is severely impaired or I am on dialysis.I am not taking strong medication that affects liver enzymes and can't stop them for the study.My heart attack symptoms started within the last 2 days.I have had serious heart failure within the last 6 months.I have not had a stroke, brain tumor, or serious head injury in the last 3 months.You have a positive test showing heart damage for NSTEMI patients.I do not have drug/alcohol abuse issues and my blood and kidney tests are within normal ranges.I cannot take ticagrelor due to health reasons.Your electrocardiogram shows certain changes that indicate heart problems.I plan to undergo a procedure to open my heart's blocked artery within 24 hours of my heart attack symptoms starting.I have had a severe heart attack.I have had a type of heart attack known as NSTEMI.My heart test shows damage to the heart muscle.I have stable chest pain due to heart disease and am scheduled for a heart procedure.You have heart-related changes on an electrocardiogram that show possible heart strain but do not meet the criteria for a certain type of heart attack.You have a specific abnormal heart reading called "ST-segment elevation" or a specific heart rhythm called "left bundle-branch block."I have received or will receive clot-dissolving drugs around my heart procedure.Your blood pressure is very high and not well controlled.My liver enzyme ALT levels are more than 2.5 times the upper limit.I have a history of severe irregular heartbeats or am at high risk for slow heart rates.You have a specific heart condition called ST-segment elevation myocardial infarction (STEMI) with certain heart test results.I have stable heart disease and am scheduled for a procedure to open my heart's arteries.I am currently taking medication for blood clots.
- Group 1: Ticagrelor
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the trial's eligibility criteria exclude adults over 25 years of age?
"To qualify for this medical trial, applicants must be between the ages of 18 and 75 years old. Alternatively, there are 56 trials available that accept participants under eighteen while 1220 studies welcome seniors aged 65 or older."
What criteria must be fulfilled to join this clinical experiment?
"This clinical trial will evaluate the efficacy of a medication for patients aged 18 to 75 with coronary artery disease. To qualify, enrollees must have an episode of stable angina or Non-ST elevation myocardial infarction (NSTEMI) in conjunction with positive biomarker tests and ST segment changes on electrocardiogram indicative of ischemia; they may also be eligible if they display signs of STEMI accompanied by plans to perform primary percutaneous coronary intervention within 24 hours."
What medical conditions is ticagrelor most commonly prescribed to treat?
"Ticagrelor is widely prescribed to assist with cerebrovascular accident, but can also be used successfully in the treatment of coronary artery disease (CAD), myocardial infarction and other high risk pathologies."
Is ticagrelor associated with any adverse effects when used by patients?
"Thanks to its Phase 4 status, ticagrelor has been approved for use and therefore scored a 3 on our safety evaluation scale."
Are any other trials being conducted with ticagrelor as the primary treatment?
"At present, 42 studies are in session examining the efficacy of ticagrelor. 11 of these trials have progressed to Phase 3 and there is considerable geographical scope with 591 sites running research on this drug - particularly concentrated around San Diego, California."
Are there still positions available for participants in this research endeavor?
"This research trial is no longer enrolling new participants. Initially posted on January 1st 2014, it was last updated in December 10th 2013. If you are searching for other medical studies related to coronary artery disease and ticagrelor, there currently exist 1234 and 42 clinical trials respectively that are actively recruiting patients."
How many individuals are currently enrolled in this research trial?
"As of December 10th 2013, this study is no longer admitting patients. It was first published on January 1st 2014 and has since been removed from the list of active trials. Those seeking clinical trial enrollment may find 1234 studies recruiting for coronary artery disease or 42 focused on ticagrelor."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger